This study is looking at a new treatment called volrustomig for women with high-risk locally advanced cervical cancer. These patients have not shown any signs of the cancer getting worse after receiving chemotherapy and radiation. The main goal is to see how well volrustomig works and how safe it is for these women.
This is a Phase 3 trial, meaning it is looking closely at how well the treatment works and its safety. The trial aims to include about 800 participants. It is regulated by the FDA.
Who can join
Women aged 15 years and older can join the study. They must have a specific type of locally advanced cervical cancer and should not have seen their cancer get worse after treatment. The trial team will check to make sure each person meets the requirements before they can participate.
Condition
Locally Advanced Cervical Cancer
Age group
All ages
Sex
Female
The study team makes the final call on eligibility.
What happens in the study
Participants will be randomly assigned to one of two groups. One group will receive volrustomig through an IV infusion, and the other group will receive a placebo, which looks like the treatment but has no active medicine. This way, researchers can compare the effects of volrustomig to that of the placebo.
Where
This trial is enrolling at 28 locations. Recruiting sites are listed first.
Treats cervical cancer, uterine cancer, ovarian cancer and vulvar cancer. Offers laparoscopic surgery, fertility-sparing surgery and prophylactic surgery.
Chief of gynecologic medical oncology, MSK. Treats cervical cancer, uterine cancer and ovarian cancer. Offers chemotherapy. The main cancer doctor for adults. Manages your treatment and your care team. Recognized at state, national or international level.